1. Home
  2. CSIQ vs CGEM Comparison

CSIQ vs CGEM Comparison

Compare CSIQ & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Canadian Solar Inc. (ON)

CSIQ

Canadian Solar Inc. (ON)

HOLD

Current Price

$12.64

Market Cap

824.4M

Sector

Technology

ML Signal

HOLD

Logo Cullinan Oncology Inc.

CGEM

Cullinan Oncology Inc.

HOLD

Current Price

$14.48

Market Cap

873.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CSIQ
CGEM
Founded
2001
2016
Country
Canada
United States
Employees
17113
N/A
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
824.4M
873.4M
IPO Year
2006
2020

Fundamental Metrics

Financial Performance
Metric
CSIQ
CGEM
Price
$12.64
$14.48
Analyst Decision
Hold
Strong Buy
Analyst Count
10
9
Target Price
$17.36
$30.11
AVG Volume (30 Days)
2.5M
713.7K
Earning Date
05-14-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$23.95
N/A
Revenue Next Year
$13.58
$5.20
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.85
$5.68
52 Week High
$34.59
$16.74

Technical Indicators

Market Signals
Indicator
CSIQ
CGEM
Relative Strength Index (RSI) 36.72 53.58
Support Level $11.00 $11.75
Resistance Level $13.73 $16.74
Average True Range (ATR) 0.83 0.97
MACD 0.02 0.11
Stochastic Oscillator 29.35 64.11

Price Performance

Historical Comparison
CSIQ
CGEM

About CSIQ Canadian Solar Inc. (ON)

Canadian Solar Inc is a Canadian solar technology and renewable energy company. It is a manufacturer of solar photovoltaic modules, a provider of battery energy storage solutions, and a developer of utility-scale solar power and battery energy storage projects.. It operates through two business segments CSI Solar and Recurrent Energy segment. The CSI Solar segment focused on solar modules and battery energy storage manufacturing and products. Its Recurrent segment focused on utility-scale solar power and battery energy storage project development and operation. Key revenue is generated from CSI Solar segment.

About CGEM Cullinan Oncology Inc.

Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.

Share on Social Networks: